Five Prime Therapeutics

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Five Prime Jumps on Progress in Gastric Cancer Drug Trial
Five Prime Therapeutics soared after it said its gastric-cancer treatment met all three of its efficacy endpoints in a Phase 2 trial.


Five Prime Therapeutics  (FPRX) - Get Report soared on Wednesday after the biotech said bemarituzumab, its treatment for gastric cancer, met all three of its efficacy endpoints in a Phase 2 trial.

Shares of the South San Francisco company at last check quadrupled to $20.88.

"These results bring us one step closer to the first potential targeted therapy for advanced gastric cancer in over a decade," Helen Collins, a physician who is executive vice president and chief medical officer, said in a statement....

https://www.thestreet.com/investing/stoc..._ven=YAHOO

Der Vollständigkeit halber - FPRX gibts nicht mehr....

Wurde von Amgen übernommen - für 38$ je Aktie....


Der US-Pharmakonzern Amgen verstärkt sich mit einer Milliardenübernahme im Biotechsektor.
04.03.2021 15:05
Wie die Amgen Inc mitteilte, wird die Five Prime Therapeutics Inc für 38,00 US-Dollar je Aktie in bar übernommen. Der Preis liegt 79 Prozent über dem Schlusskurs der Aktie vom Mittwoch. Five Prime Therapeutics werde dadurch mit 1,9 Milliarden Dollar bewertet. Abgeschlossen werden soll der Deal im zweiten Quartal.
NEW YORK (Dow Jones)

https://www.finanzen.net/nachricht/aktie...cs-9879820


Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
Apr 16, 2021, 08:25 ET
THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses.

https://www.prnewswire.com/news-releases...70601.html